VANCENASE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANCENASE (VANCENASE).
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, leading to inhibition of inflammatory mediators such as cytokines and prostaglandins.
| Metabolism | Hepatic via cytochrome P450 3A4 (CYP3A4) to active metabolite beclomethasone-17-monopropionate, which is further metabolized. |
| Excretion | Primarily hepatic metabolism; excreted in urine (approximately 10% as unchanged drug and metabolites) and feces (approximately 80% as metabolites). |
| Half-life | Terminal elimination half-life is approximately 3.5 hours after intranasal administration. Clinically, this short half-life supports twice-daily dosing for sustained effect. |
| Protein binding | Approximately 87% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 2.6 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Intranasal: approximately 50% systemic bioavailability due to direct absorption across nasal mucosa and some gastrointestinal absorption from swallowed portion. Oral: low and variable (approximately 20%) due to first-pass metabolism. |
| Onset of Action | Intranasal: clinical effect may be observed within 12-24 hours, with maximal benefit often after several days of regular use. |
| Duration of Action | Duration of action is approximately 12-24 hours after intranasal administration, supporting twice-daily dosing. Effects are maintained with regular use. |
1-2 inhalations (50-100 mcg) per nostril twice daily (100-200 mcg/day total).
| Dosage form | AEROSOL, METERED |
| Renal impairment | No adjustment required for renal impairment. |
| Liver impairment | No adjustment required for hepatic impairment. |
| Pediatric use | Age 6-11 years: 1 inhalation (50 mcg) per nostril once daily, may increase to twice daily if needed. Age 12-17 years: same as adult. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VANCENASE (VANCENASE).
| Breastfeeding | Beclomethasone is excreted in breast milk in small amounts. Inhaled corticosteroids at therapeutic doses are considered compatible with breastfeeding. The milk-to-plasma ratio is not well established for beclomethasone; assume low due to extensive first-pass metabolism. Risks to infant are negligible at maternal inhaled doses. |
| Teratogenic Risk | VANCENASE (beclomethasone dipropionate) is an inhaled corticosteroid. In animal studies, corticosteroids have been shown to be teratogenic. However, inhaled corticosteroids at recommended doses are not associated with a significant increase in congenital malformations. First trimester: Limited data, but no clear evidence of increased risk. Second and third trimesters: Risk of intrauterine growth restriction (IUGR) with prolonged high-dose systemic exposure; inhaled doses minimize systemic absorption. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to beclomethasone or any component of the formulation","Status asthmaticus or other acute episodes of asthma"]
| Precautions | ["Nasal irritation, epistaxis, and nasal septal perforation","Potential for systemic corticosteroid effects with prolonged use (e.g., adrenal suppression, growth retardation in children)","Avoid use in patients with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections","Use with caution in patients with recent nasal surgery or trauma"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal asthma control, fetal growth (serial ultrasounds for IUGR if high-dose or prolonged systemic use), and maternal blood glucose (corticosteroids may increase insulin resistance). Assess for signs of adrenal suppression in mother if used long-term at high doses. |
| Fertility Effects | No known adverse effects on human fertility. In animal studies, corticosteroids may impair fertility at high systemic doses, but inhaled beclomethasone at therapeutic doses is unlikely to affect fertility. |